Bio-pharmaceutical industry development fast
Custom Synthesis,With the deepening of the strategy of “healthy China”, the health demand of domestic residents continues to grow, which has led to the outbreak of the biomedical industry. This year, the domestic biopharmaceutical companies listed, mergers and acquisitions cases continue to emerge, the entire industry has entered the active period of innovation.
Statistics show that the global market for innovative drugs is close to $600 billion trillion, while our country is less than $10 billion trillion. However, with the start of the national drug regulatory reform in recent years, China’s biomedical industry gradually into the development of fast lane, attracting the attention of many investors.
Founded only 3 years, the Nasdaq successfully listed in the United States. Shares rose 55% on the first day of the IPO, up to $1.3 billion. This previously only in the Internet industry to see the speed of listing in Shanghai Zhangjiang, a new drug research and development Enterprises-Ding medicine body.
Through with independent research and development and cross-border cooperation, Ding is committed to oncology, anti-infection and autoimmune areas as soon as possible to develop products to meet the needs of domestic patients. Before Ding, the Wuxi group’s drug-ming organism is listed in Hong Kong this year.http://www.haihengpharma.com/bio-pharmaceutical-industry-development-fast/News